Cartilage Oligomeric Matrix Protein (COMP) in systemic sclerosis (SSc): Role in disease severity and subclinical rheumatoid arthritis overlap

被引:24
|
作者
Gheita, Tamer A. [1 ]
Hussein, Hani [1 ]
机构
[1] Cairo Univ, Fac Med, Dept Chem Pathol, Cairo, Egypt
关键词
Systemic sclerosis; COMP; RA overlap; CYCLIC CITRULLINATED PEPTIDE; CLASSIFICATION CRITERIA; JOINT INVOLVEMENT; AMERICAN-COLLEGE; ANTIBODIES; FEATURES; ARTHROPATHY; PREVALENCE; DETECT;
D O I
10.1016/j.jbspin.2011.02.022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of the present study was to compare the serum level of COMP in both subsets of Systemic sclerosis (SSc) as a marker of arthritis and reveal an associated subclinical RA overlap and a relation to clinical, laboratory and radiological findings in SSc. Methods: Forty adult SSc patients were included in the study and grouped into the two subsets diffuse (dSSc) and limited (lSSc) SSc. Their mean age was 40 +/- 9 years. Thorough history taking and clinical examination were performed to all patients. Skin thickness was scored according to the modified Rodnan skin score method (MRSS). The disease activity was assessed by measuring the Medsger severity score. The joints were extensively examined and the tenderness counted according to the Ritchie articular index (RAI). Relevant laboratory and radiological investigations were carried out. The serum COMP level was determined by ELISA. Results: The serum COMP was significantly higher in the SSc patients compared to the control and obviously higher in the dSSc compared to the lSSc patients. The level of COMP was higher in the females and significantly higher in the SSc patients with arthritis (56.5 +/- 6.8 ug/ml) compared to those without (34 +/- 8.3 ug/ml) (P 0.000). Conclusion: The COMP level may become a nonspecific but useful marker for joint involvement in SSc patients to identify patients at risk of joint damage and developing SSc-RA overlap syndrome even with mild arthritis. (C) 2011 Societe francaise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:51 / 56
页数:6
相关论文
共 50 条
  • [41] Antibodies to Cartilage Oligomeric Matrix Protein Are Pathogenic in Mice and May Be Clinically Relevant in Rheumatoid Arthritis
    Ge, Changrong
    Tong, Dongmei
    Loennblom, Erik
    Liang, Bibo
    Cai, Weiwei
    Fahlquist-Hagert, Cecilia
    Li, Taotao
    Kastbom, Alf
    Gjertsson, Inger
    Dobritzsch, Doreen
    Holmdahl, Rikard
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 (06) : 961 - 971
  • [42] Cartilage oligomeric matrix protein/thrombospondin-5 (COMP/TSP-5) levels do not correlate to functional class in patients with rheumatoid arthritis
    Andrade, Fernanda Duarte
    Bender, Ana Ligia
    da Silveira, Ines Guimaraes
    Stein, Helga
    von Muehlen, Carlos Alberto
    Staub, Henrique Luiz
    CLINICAL RHEUMATOLOGY, 2009, 28 (12) : 1441 - 1442
  • [43] Cartilage oligomeric matrix protein/thrombospondin-5 (COMP/TSP-5) levels do not correlate to functional class in patients with rheumatoid arthritis
    Fernanda Duarte Andrade
    Ana Lígia Bender
    Inês Guimarães da Silveira
    Helga Stein
    Carlos Alberto von Mühlen
    Henrique Luiz Staub
    Clinical Rheumatology, 2009, 28 : 1441 - 1442
  • [44] CARTILAGE OLIGOMERIC MATRIX PROTEIN, A BIOMARKER OF ARTHRITIS, COULD BE USEFUL FOR PREDICTING THE RESPONSE TO BIOLOGIC THERAPY IN RHEUMATOID ARTHRITIS?
    Gavrila, B. I.
    Ciofu, C.
    Mihai, C.
    Udrea, G.
    Bojinca, M.
    Stoica, V.
    Panaitescu, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1179 - 1180
  • [45] CARTILAGE OLIGOMERIC MATRIX PROTEIN, A BIOMARKER OF ARTHRITIS, COULD IT BE USEFUL FOR PREDICTING THE RESPONSE TO BIOLOGIC THERAPY IN RHEUMATOID ARTHRITIS?
    Ciofu, Claudia
    Macovei, Liviu
    Ancuta, Ioan
    Bojinca, Mihai
    Stoica, Victor
    Gavrila, Bogdan Ion
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S3 - S3
  • [46] Role of the calcium-binding domain in cartilage oligomeric matrix protein (COMP) on its synthesis and secretion.
    Yusuke, H
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S224 - S224
  • [47] Can Tocilizumab Decrease Cartilage Oligomeric Matrix Protein Levels and Disease Activity in Patients with Long-Standing Rheumatoid Arthritis?
    Benucci, Maurizio
    Meacci, Francesca
    Manfredi, Mariangela
    Li Gobbi, Francesca
    Infantino, Maria
    Ricci, Cristian
    Sarzi-Puttini, Piercarlo
    Atzeni, Fabiola
    CURRENT RHEUMATOLOGY REVIEWS, 2014, 10 (02) : 131 - 135
  • [48] Regulation of Complement by Cartilage Oligomeric Matrix Protein Allows for a Novel Molecular Diagnostic Principle in Rheumatoid Arthritis
    Happonen, Kaisa E.
    Saxne, Tore
    Aspberg, Anders
    Morgelin, Matthias
    Heinegard, Dick
    Blom, Anna M.
    ARTHRITIS AND RHEUMATISM, 2010, 62 (12): : 3574 - 3583
  • [49] INCREASED SERUM CONCENTRATIONS OF CARTILAGE OLIGOMERIC MATRIX PROTEIN - A PROGNOSTIC MARKER IN EARLY RHEUMATOID-ARTHRITIS
    FORSLIND, K
    EBERHARDT, K
    JONSSON, A
    SAXNE, T
    BRITISH JOURNAL OF RHEUMATOLOGY, 1992, 31 (09): : 593 - 598
  • [50] Diverse mutations in the cartilage oligomeric matrix protein (COMP) gene in the pseudoachondroplasia multiple epiphyseal dysplasia disease spectrum
    Cohn, DH
    Briggs, MD
    Goodart, S
    King, LM
    Golik, SS
    Rimoin, DL
    Knowlton, RG
    JOURNAL OF INVESTIGATIVE MEDICINE, 1996, 44 (01) : A95 - A95